Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized,Single-Blind, Placebo-controlled, Self-matched Pairing, Independent Evaluated Study to Evaluate the Efficacy and Safety of RGN-137 Topical Gel in Subjects With Junctional and Dystrophic Epidermolysis Bullosa

Trial Profile

A Randomized,Single-Blind, Placebo-controlled, Self-matched Pairing, Independent Evaluated Study to Evaluate the Efficacy and Safety of RGN-137 Topical Gel in Subjects With Junctional and Dystrophic Epidermolysis Bullosa

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Nov 2018

At a glance

  • Drugs Timbetasin (Primary)
  • Indications Epidermolysis bullosa
  • Focus Therapeutic Use
  • Sponsors G-treeBNT; Lenus Therapeutics
  • Most Recent Events

    • 11 Nov 2018 Status changed from not yet recruiting to recruiting.
    • 02 Nov 2018 Planned initiation date changed from 1 Nov 2018 to 1 Nov 2019.
    • 11 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top